Psoriatic Arthritis
Conference Coverage
Infliximab biosimilar posts mostly reassuring data in Norway’s NOR-SWITCH study
WASHINGTON – Data from the first randomized trial of switching from an originator biologic to a biosimilar of the originator indicate that the...
Conference Coverage
First JAK inhibitor in psoriatic arthritis achieves results similar to adalimumab
WASHINGTON – Tofacitinib demonstrated efficacy comparable to adalimumab in patients with active psoriatic arthritis and an inadequate response to...
Conference Coverage
Tofacitinib effective after TNFi failure
WASHINGTON – The oral Janus kinase inhibitor tofacitinib is safe and effective in patients with active psoriatic arthritis and an inadequate...
Conference Coverage
Guselkumab appears safe, effective for psoriatic arthritis
WASHINGTON - The investigational anti-interleukin-23 monoclonal antibody guselkumab was safe and well tolerated, and demonstrated significant...
Tips
Debunking Psoriasis Myths: Do Psoriasis Therapies Cause Depression?
Conference Coverage
Abatacept makes inroads in psoriatic arthritis
WASHINGTON – Abatacept achieved promising results in patients with psoriatic arthritis through 24 weeks of treatment in a placebo-controlled,...
Conference Coverage
VIDEO: Consider comorbidities when preparing patients for systemic psoriasis therapy
LAS VEGAS – Clinicians should consider the increased risk for multiple comorbidities in their patients with psoriasis, Joel M. Gelfand, MD, said...
Conference Coverage
Optimize anti–TNF-alpha therapy for psoriasis
Anti–TNF-alpha medications have shown effectiveness for psoriasis, but ongoing issues include optimizing therapy, managing treatment in special...
Conference Coverage
VIDEO: IL-23 inhibitors on the upswing
LAS VEGAS
Conference Coverage
Study offers reassuring data on certolizumab use in pregnancy
VIENNA – Consider off-label certolizumab in women with psoriasis who need a biologic and are pregnant or planning to become so.
Conference Coverage
What good are biosimilars if patients won’t use them?
BOSTON – The only meaningful measure of the success of biosimilar drugs for arthritis is whether patients use them.